Various neuroendocrine tumors, gliomas, and Parkinson’s disease
Conditions
Interventions
Gold Standard:For tumor patients: pathological confirmation
For Parkinson’s disease: diagnosis based on the 2015 International Parkinson and Movement Disorder Society (MDS-PD) clinical diagnostic criteria.
Index test:[18F]FDOPA PET/CT imaging
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Voluntarily participates in this clinical study and signs a written informed consent form prior to any study-related procedures. (2) Has an expected survival of more than 3 months. (3) Patients with pathologically confirmed or clinically highly suspected pheochromocytoma/paraganglioma, neuroblastoma, glioma, gastrointestinal carcinoid tumor, medullary thyroid carcinoma, or clinically diagnosed Parkinson’s disease. (4) Newly diagnosed patients, or those who have completed prior antitumor therapy at least =1 month before enrollment. (5) Women and men of childbearing potential must agree to use strict and effective contraception after signing the informed consent, throughout the study period, and for 6 months after study completion. During the same period, male participants must refrain from donating sperm and female participants must not undergo oocyte cryopreservation. Women of childbearing potential must have a negative pregnancy test within 3 days prior to the first administration. (6) ECOG performance status of 0–1.
Exclusion criteria
Exclusion criteria: (1) Pregnant or breastfeeding patients. (2) Patients with impaired renal function, defined as a creatinine clearance < 40 mL/min. (3) Patients with concurrent primary malignant tumors. (4) Patients who have not signed the informed consent form or are unable to comply with study procedures. (5) ECOG performance status = 2. (6) Any other condition deemed unsuitable for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| maximum standardized uptake;Specificity;Sensitivity;Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| mean standardized uptake; | — |
Countries
China
Contacts
Public ContactYueqi Wang
West China Hospital of Sichuan University
Outcome results
None listed